[HTML] from ascopubs.orgEA Perez, EH Romond, VJ Suman… - Journal of Clinical …, 2011 - jco.ascopubs.org Purpose Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses of four large trials. Initial data of the combined analysis of the North ...
[HTML] from jacccardiovascularinterventions.comC Spaulding, E Teiger, P Commeau… - JACC …, 2011 - interventions.onlinejacc.org Background: Concern over the safety of drug-eluting stents implanted during PCI for STEMI remains, and long-term follow-up from randomized trials are necessary. TYPHOON (Trial to assess the use of the cYPHer sirolimus-eluting stent in acute myocardial infarction treated with ... Cited by 5 - Related articles - All 4 versions
H Yan, HS Choe, SW Nam, Y Hu… - Nature, 2011 - mitre.org A nanoprocessor constructed from intrinsically nanometer-scale building blocks is an essential component for controlling memory, nanosensors and other functions proposed for nanosystems assembled from the bottom up. Important steps towards this goal over the past fifteen ... Cached
[HTML] from thelancet.comL Gianni, U Dafni, RD Gelber, E Azambuja… - The Lancet …, 2011 - Elsevier The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant, adjuvant chemotherapy, or both in patients with HER2-positive early breast cancer. The primary ... Cited by 7 - Related articles - All 7 versions
MA Vink, MT Dirksen, MJ Suttorp… - JACC …, 2011 - interventions.onlinejacc.org Background: In primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction (STEMI), the use of drug-eluting stents (DES) is still controversial. Several randomized controlled trials of DES, compared with bare-metal stents (BMS), with short-term follow-up ... Cited by 5 - Related articles - All 4 versions